2022 International Conference on Gram Positive Pathogens

项目摘要 革兰氏阳性病原体国际会议(ICGPP)汇集了所有阶段的科学家 他们的事业是交流思想和研究战略，源于对革兰氏阳性菌的共同兴趣 病原体。该会议最初于2006年举行，随后在2008年、2010年、2012年、2014年、2016年和2018年继续举行 由于参与者的热情，来自加州大学的研究人员之间的合作 内布拉斯加州医学中心等美国大平原地区的学术机构。这个 ICGPP的主要好处是让研究人员有机会分享科学、方法和方案 这是革兰氏阳性细菌所特有的，而不是革兰氏阴性细菌。而革兰氏阳性病原体 引起无数感染，从抗生素相关性结肠炎到坏死性筋膜炎，基本方面 生物功能，如跨膜的蛋白质分泌、细胞壁生物合成和蛋白质 在这组医学上重要的细菌之间共享锚定和细胞间的通信。这个 革兰氏阳性感染的影响继续增长，抗生素耐药性仍然是一个重大威胁。AS 一个例子，艰难梭状芽胞杆菌小肠结肠炎，曾经主要与医院使用抗生素有关，现在 在与医疗机构没有流行病学关系的年轻、健康的成年人中发现。近期 数据表明，艰难梭菌引起的感染是抗生素耐药患者死亡的主要原因 细菌在美国。此外，社区获得性耐甲氧西林金黄色葡萄球菌(CA-MRSA) USA300菌株继续在学校、更衣室和医院引起皮肤和软组织感染 其他健康的个体。此R13申请正在申请资金，以支持将举行的第八届ICGPP 2022年10月9日至12日在内布拉斯加州奥马哈举行。我们多元化的组织和科学委员会由十个成员组成 来自不同学术机构的首席调查人员代表了所有与医学相关的克- 阳性细菌。尽管在美国也有其他会议讨论细菌致病的各个方面 或原核生物，这是唯一一次专门关注革兰氏阳性发病机制和生物学的会议， 并提供一个合作和支持的环境，促进已建立的 调查人员和初级科学家。年轻的科学家可以选择在任一海报中展示他们的研究 或口头形式，2018年，在27名非主旨演讲者中，17名实习生和8名助理教授发表了 口头研究报告。四位国际知名科学家已经同意发表主旨演讲 在2022年ICGPP上的演讲：Andreas Peschel博士(图宾根大学)，Drusilla Burns(美国食品和 药品管理局)、Shonna McBride(埃默里大学)和Jose Lemos(佛罗里达大学)。留住 参赛者的注册费较低，为了鼓励年轻调查人员的参与，我们要求提供资金 以支持我们的主旨演讲者的旅行，以及将授予受训人员的20项旅行补助金。

Project Summary The International Conference on Gram-Positive Pathogens (ICGPP) brings together scientists at all stages of their careers to exchange ideas and research strategies stemming from shared interests in gram-positive pathogens. This conference, initially held in 2006 and then continued in 2008, 2010, 2012, 2014, 2016, and 2018 because of participant enthusiasm, grew out of collaborations between investigators at the University of Nebraska Medical Center and other academic institutions in the great plains region of the United States. The overarching benefit of ICGPP is the opportunity for investigators to share the science, approaches, and protocols that are unique to gram-positive bacteria in contrast to gram-negative bacteria. While gram-positive pathogens cause myriad infections, ranging from antibiotic-associated colitis to necrotizing fasciitis, fundamental aspects of biological function such as protein secretion across single membranes, cell wall biosynthesis and protein anchoring, and cell-cell communication are shared between this group of medically important bacteria. The impact of gram-positive infections continues to grow, and antibiotic resistance remains a significant threat. As an example, Clostridioides difficile enterocolitis, once primarily associated with antibiotic use in hospitals, is now found in young, healthy adults that do not have an epidemiological relationship to a healthcare facility. Recent data suggests that infections caused by C. difficile are the leading cause of mortality among antibiotic-resistant bacteria in the US. In addition, community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) strain USA300 continues to cause skin and soft tissue infections in schools, locker rooms, and hospitals in otherwise healthy individuals. This R13 application is requesting funds to support the 8th ICGPP to be held October 9 -12, 2022 in Omaha, Nebraska. Our diverse organizing and scientific committee comprises ten principal investigators from various academic institutions representing the full range of medically relevant gram- positive bacteria. Although other meetings exist in the US that cover various aspects of bacterial pathogenesis or prokaryotic biology, this is the only meeting focused specifically on gram-positive pathogenesis and biology, and which provides a collegial and supportive environment that fosters interactions between established investigators and junior scientists. Young scientists have the option of presenting their research in either poster or oral format and, in 2018, out of the 27 non-keynote speakers, 17 trainees and 8 Assistant Professors gave oral research presentations. Four internationally known scientists have already agreed to give keynote presentations at the 2022 ICGPP: Drs. Andreas Peschel (University of Tubingen), Drusilla Burns (U.S. Food and Drug Administration), Shonna McBride (Emory University) and Jose Lemos (University of Florida). To keep registration fees low for participants and to encourage the engagement of young investigators, we request funds to support travel of our keynote speakers and for 20 travel grants that will be awarded to trainees.